• TRIAL DATA

    Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC

    This multicenter, randomized phase 3 trial evaluated first-line anlotinib versus bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Nature via Google News)